Alumis (ALMS) Assets Average (2024 - 2026)
Alumis (ALMS) posted quarterly Assets Average of $450.0 million for Q4 2025, up 19.43% year-over-year from $376.8 million in Q4 2024, and down 18.11% quarter-over-quarter from $549.5 million in Q3 2025.
Alumis (ALMS) Assets Average (2024 - 2026) Analysis & Trends
Alumis (ALMS) has reported Assets Average for 2 consecutive years, with $450.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Assets Average rose 19.43% year-over-year to $450.0 million; the TTM figure through Dec 2025 stood at $450.0 million (up 19.43% YoY), while the FY2025 annual figure was $376.5 million, up 74.85% from the prior year.
- Assets Average slipped to $450.0 million in Q4 2025 per ALMS's latest filing, from $549.5 million in the prior quarter.
- Across five years, Assets Average topped out at $549.5 million in Q3 2025 and bottomed at $301.1 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.32 Bn | 132.47 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 63.35 Bn | 58.16 Bn | 1.37 Bn | - |
| 4 | Moderna | 63.15 Bn | 58.01 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.96 Bn | 36.86 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Royalty Pharma | 27.67 Bn | 26.83 Bn | - | 19.82 Bn |
| 8 | BioNTech SE | 27.52 Bn | 9.13 Bn | 668.28 Mn | 25.27 Bn |
| 9 | Insmed | 26.98 Bn | 25.82 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Alumis | 3.06 Bn | 2.56 Bn | - | 486.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 486.28 Mn |
| Dec 31, 2025 | 449.98 Mn |
| Sep 30, 2025 | 549.47 Mn |
| Jun 30, 2025 | 436.11 Mn |
| Mar 31, 2025 | 301.15 Mn |
| Dec 31, 2024 | 376.78 Mn |
| Sep 30, 2024 | 338.87 Mn |